# BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)

> **NCT01354431** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 168 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** nivolumab
- **BIOLOGICAL:** nivolumab

## Key facts

- **NCT ID:** NCT01354431
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-31
- **Primary completion:** 2013-05-15
- **Final completion:** 2021-04-15
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2022-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01354431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01354431, "BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01354431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*